What is the stock price of Alkermes plc?
Alkermes plc's stock symbol is ALKS and currently trades under NASDAQ. It’s current price per share is approximately $ 30.69. When is Alkermes plc's next earnings date?
What price target do analysts set for AlkS?
What price target have analysts set for ALKS? 10 Wall Street analysts have issued twelve-month price objectives for Alkermes' stock. Their forecasts range from $15.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $20.50 in the next year.
Where can I buy AlkS shares?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What are the price targets for Alkermes'shares?
11 analysts have issued 1 year price targets for Alkermes' shares. Their forecasts range from $20.00 to $36.00. On average, they expect Alkermes' share price to reach $28.70 in the next year. This suggests a possible upside of 58.1% from the stock's current price. View Analyst Price Targets for Alkermes.
When will Alkermes report its second quarter results?
What is Alkermes' IL-2?
Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021. Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 28, 2021 to discuss the company's second quarter 2021 financial results.
What is a fast track drug?
Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy. The data are being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021, and in an investor webcast presentation hosted by the company.
Pre-Market Trades
Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, for the treatment of mucosal melanoma.
About Pre-Market Quotes
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
How much does Alkermes make?
Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.
Is Alkermes a hold?
Alkermes has a market capitalization of $3.93 billion and generates $1.04 billion in revenue each year. The company earns $-110,860,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.
